Search results for "load"

showing 10 items of 1967 documents

Assessment of prevalence and load of torquetenovirus viraemia in a large cohort of healthy blood donors.

2020

OBJECTIVES: Torquetenovirus (TTV) is an emerging marker of functional immune competence with the potential to predict transplant-related adverse events. A large-scale epidemiological study was performed to understand how basal values vary in healthy individuals according to age and gender.; METHODS: We tested plasma from 1017 healthy blood donors aged 18-69years. The presence and load of TTV were determined by a real-time PCR assay. A sub-cohort of 384 donors was tested for anti-cytomegalovirus IgG antibodies, and 100 participants were also tested for TTV viraemia on a paired whole blood sample.; RESULTS: The overall prevalence of TTV was 65% (657/1017) with a mean (±SD) growth of 5±4% ever…

0301 basic medicineMicrobiology (medical)AdultMalemedicine.medical_specialtyAgingAdolescentprevalence030106 microbiologyPcr assayPhysiologyTTVViremiaBlood DonorsanelloviridaeReal-Time Polymerase Chain Reaction03 medical and health sciencesPlasmaYoung Adult0302 clinical medicineEpidemiologyMedicineHumansBlood Transfusion030212 general & internal medicineViremiaTTV; anelloviridae; blood donors; healthy controls; prevalence; torquetenovirus; viremiaAdverse effectWhole bloodAgedTorque teno virusbiologybusiness.industryGeneral MedicineMiddle AgedViral Loadmedicine.diseaseDNA Virus InfectionsHealthy VolunteersLarge cohorttorquetenovirusInfectious DiseasesHealthy individualsDNA Viralbiology.proteinhealthy controlsFemaleAntibodybusinessClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
researchProduct

Epidemiological Surveillance of Norovirus and Rotavirus in Sewage (2016–2017) in Valencia (Spain)

2020

© 2020 by the authors.

0301 basic medicineMicrobiology (medical)RotavirusVeterinary medicineGenotypingVirus RNA030106 microbiologyPopulationSewagenorovirusMicroorganismesBiologymedicine.disease_causeMicrobiologyArticle03 medical and health sciencesAigües residuals MicrobiologiaVirologyRotavirusGenotypemedicinesewageeducationGenotypinglcsh:QH301-705.5education.field_of_studyMolecular epidemiologySewagebusiness.industryNorovirus030104 developmental biologyrotaviruslcsh:Biology (General)genotypingNorovirusbusinessViral load
researchProduct

Murine cytomegalovirus (CMV) infection via the intranasal route offers a robust model of immunity upon mucosal CMV infection

2016

Cytomegalovirus (CMV) is a ubiquitous virus, causing the most common congenital infection in humans, yet a vaccine against this virus is not available. Experimental studies of immunity against CMV in animal models of infection, such as the infection of mice with mouse CMV (MCMV), have relied mainly on parenteral infection protocols, although the virus naturally transmits by mucosal routes via body fluids. To characterize the biology of infections by mucosal routes, we compared the kinetics of virus replication, latent viral load and CD8 T-cell responses in lymphoid organs upon experimental intranasal (targeting the respiratory tract) and intragastric (targeting the digestive tract) infectio…

0301 basic medicineMuromegalovirusMice 129 StrainCongenital cytomegalovirus infectionSpleenCD8-Positive T-LymphocytesBiologyVirus ReplicationVirus03 medical and health sciencesImmunityVirologyVirus latencymedicineAnimalsImmunity MucosalMice Inbred BALB CAnimal StructuresViral Loadmedicine.diseaseVirologyVirus Latency030104 developmental biologymedicine.anatomical_structureLymphatic systemViral replicationModels AnimalImmunologyFemaleViral load
researchProduct

Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART

2018

Objectives We evaluated the association between pre-ART HIV DNA and HIV-infected participant characteristics at baseline as well as with their response to first-line ART. Methods Four hundred and thirty-three patients from the ICONA cohort, starting first-line ART after the year 2000, were analysed. Pre-ART HIV DNA was quantified with the modified COBAS TaqMan HIV-1 Test and normalized by CD4+ T cells. Linear correlation between pre-ART HIV DNA and other continuous markers (HIV RNA, CD4 count, markers of inflammation and coagulation) at baseline was evaluated by means of Pearson correlation coefficient and a linear regression model. Survival analyses and Cox regression models were used to s…

0301 basic medicineOncologyCD4-Positive T-LymphocytesMaleHIV InfectionsSettore MED/07chemistry.chemical_compoundHIV InfectionPharmacology (medical)ViralProspective StudiesProspective cohort studyAntiinfective agentAdult; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; DNA Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome; Viral LoadMiddle AgedViral LoadvirologyHIV CD4Stavudinemedicine.anatomical_structureInfectious DiseasesTreatment Outcomehiv-1 t-lymphocytes virology blood hiv rna hiv dnaAnti-Retroviral AgentsCD4-Positive T-Lymphocyteblood hiv rnaCohorthiv dnaFemaleSurvival AnalysiViral loadARTHumanMicrobiology (medical)Adultmedicine.medical_specialtyAntiretroviral Therapy CD4 Lymphocyte Count StavudineT cellAntiretroviral TherapySettore MED/17 - MALATTIE INFETTIVENO03 medical and health sciencesInternal medicinemedicineHumanst-lymphocytesSurvival analysisPharmacologybusiness.industryProportional hazards modelHIVDNASurvival AnalysisCD4 Lymphocyte CountProspective Studie030104 developmental biologychemistryDNA ViralHIV-1Anti-Retroviral AgentbusinessDNA
researchProduct

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and pac…

2018

Summary Purpose To investigate the safety and clinical activity of comprehensive human epidermal growth factor receptor (HER) family receptor inhibition using lumretuzumab (anti-HER3) and pertuzumab (anti-HER2) in combination with paclitaxel in patients with metastatic breast cancer (MBC). Methods This phase Ib study enrolled 35 MBC patients (first line or higher) with HER3-positive and HER2-low (immunohistochemistry 1+ to 2+ and in-situ hybridization negative) tumors. Patients received lumretuzumab (1000 mg in Cohort 1; 500 mg in Cohorts 2 and 3) plus pertuzumab (840 mg loading dose [LD] followed by 420 mg in Cohorts 1 and 2; 420 mg without LD in Cohort 3) every 3 weeks, plus paclitaxel (8…

0301 basic medicineOncologyMaleReceptor ErbB-3Receptor ErbB-2Medizinchemistry.chemical_compound0302 clinical medicineErbB3Phase I StudiesAntineoplastic Combined Chemotherapy ProtocolsMedicinePharmacology (medical)skin and connective tissue diseasesMiddle AgedMetastatic breast cancerMetastatic breast cancerDiarrheaOncologyPaclitaxel030220 oncology & carcinogenesisMarcadors bioquímicsCohortFemalePertuzumabmedicine.symptommedicine.drugAdultDiarrheamedicine.medical_specialtyLoperamidePaclitaxelMama -- Càncer -- TractamentAntineoplastic AgentsBreast NeoplasmsHypokalemiaAntibodies Monoclonal HumanizedLoading dosePolymorphism Single Nucleotide03 medical and health sciencesPhase IHuman epidermal growth factor receptor 3 (HER3)Internal medicineHumansAgedPharmacologyPertuzumabbusiness.industryBiomarkerLumretuzumabmedicine.disease030104 developmental biologychemistryHuman epidermal growth factor receptor 2 (HER2)businessHeregulin (HRG)
researchProduct

Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or…

2016

Background: IMAB362, a chimeric monoclonal antibody that mediates specific killing of cancer cells expressing the tight junction protein Claudin18.2 (CLDN18.2) by activation of immune effector mechanisms, has demonstrated single-agent activity and tolerability in patients ( pts) with heavily pretreated gastric cancer. Methods: Pts with advanced/recurrent gastric and GEJ cancer were centrally evaluated for CLDN18.2 expression by immunohistochemistry (CLAUDETECT® 18.2 Histology Kit). Eligible pts had a CLDN18.2 expression of ≥2+ in ≥40% tumor cells, an ECOG PS of 0–1 and were not eligible for trastuzumab. Pts were randomized 1:1 to first-line EOX (epirubicin 50 mg/m2 and oxaliplatin 130 mg/m2…

0301 basic medicineOncologymedicine.medical_specialtybusiness.industryCancerHematologymedicine.diseaseLoading doseOxaliplatinCapecitabine03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyTolerabilityTrastuzumab030220 oncology & carcinogenesisInternal medicineMedicineAdenocarcinomabusinessEpirubicinmedicine.drugAnnals of Oncology
researchProduct

11 and 15-month-old infants do not compensate immediately for energy variation, and no further adjustment occurs 12 or 24 hours later

2021

International audience; Previously, we demonstrated that, in the short term, infants undercompensated for the energy from a preload given 25 min before an ad libitum meal. However, although not consistent, there is evidence in young children that caloric adjustment may occur over longer periods. We investigated the extent to which further energy adjustment occurs up to 24 h after a single meal preceded by preloads of varying energy density (ED) in infants that are 11 and 15 months old. Short-term caloric adjustment was measured in 11- and 15-month-old infants through a preload paradigm meal in the laboratory. To assess their caloric adjustment over longer periods (12 and 24 h), we used 24 h…

0301 basic medicinePediatricsmedicine.medical_specialtyAppetite controlCOMPXEnergy balanceAppetite030209 endocrinology & metabolism03 medical and health sciences0302 clinical medicineappetite controlpreload paradigmmedicineHumansChildMealsGeneral PsychologyMeal[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics030109 nutrition & dieteticsNutrition and DieteticsAppetite Regulationbusiness.industrydigestive oral and skin physiologyInfantCaloric theoryDiet RecordsPreloadChild Preschooldietary recordEnergy densityEnergy variationenergy intakecaloric adjustmentmedicine.symptomEnergy MetabolismbusinessWeight gain[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
researchProduct

Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants.

2019

Abstract Objectives In the absence of consensus, the present meta-analysis was performed to determine an optimal dosing regimen of vancomycin for neonates. Methods A ‘meta-model’ with 4894 concentrations from 1631 neonates was built using NONMEM, and Monte Carlo simulations were performed to design an optimal intermittent infusion, aiming to reach a target AUC0–24 of 400 mg·h/L at steady-state in at least 80% of neonates. Results A two-compartment model best fitted the data. Current weight, postmenstrual age (PMA) and serum creatinine were the significant covariates for CL. After model validation, simulations showed that a loading dose (25 mg/kg) and a maintenance dose (15 mg/kg q12h if &lt…

0301 basic medicinePediatricsvancomycininfusion procedures0302 clinical medicinenewbornMedicinePharmacology (medical)Randomized Controlled Trials as Topiceducation.field_of_studyMaintenance doseAnti-Bacterial Agents3. Good healthInfectious Diseasesdrug maintenance doseResearch DesignArea Under CurveData Interpretation Statisticalcreatinine testsVancomycinMonte Carlo Methodmedicine.drugMicrobiology (medical)medicine.medical_specialty030106 microbiologyPopulationGestational AgeMicrobial Sensitivity TestsLoading doseRS03 medical and health sciencesPharmacokineticsdrug loading dose030225 pediatricsHumanssteady stateeducationPharmacologyDose-Response Relationship Drugbusiness.industryBody WeightInfant NewbornPostmenstrual AgeinfantNONMEMRegimen[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieregimen[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessserum
researchProduct

Microbial Colonization of the Peri-Implant Sulcus and Implant Connection of Implants Restored With Cemented Versus Screw-Retained Superstructures: A …

2016

The aim of this study is to investigate peri-implant and intraconnection microflora of healthy implants restored with cemented and screwed superstructures.Patients with two to three implants restored with cemented or screwed restorations and 5 years of follow-up were recruited. Samples were taken from peri-implant sulci, adjacent teeth, and the inner portion of connections. Prevalence of positive sites and bacterial loads for 10 microorganisms were obtained with quantitative real-time polymerase chain reaction. Implant connection permeability to the studied microorganisms was estimated using a standardized bacterial contamination index. Statistical analysis was performed using a generalized…

0301 basic medicinePeri-implantitisCross-sectional studyDental implantmedicine.medical_treatmentDentistryReal-Time Polymerase Chain ReactionProsthesisOsseointegration03 medical and health sciences0302 clinical medicinemedicineHumansDental implantDental Implantsimplant-supportedbusiness.industrymicrobiologydental implant abutment design030206 dentistrySulcusdental prosthesesBacterial Load030104 developmental biologymedicine.anatomical_structureDental Implant-Abutment DesignCross-Sectional StudiesPeriodonticsImplantDental implant; dental implant abutment design; dental prostheses implant-supported; microbiology; peri-implantitis; prosthesis.Dental Prosthesis Implant-Supportedprosthesisbusinessperi-implantitisJournal of periodontology
researchProduct

Computational analysis of macrolides as SARS-CoV-2 main protease inhibitors: a pattern recognition study based on molecular topology and validated by…

2021

Since the outbreak of the current SARS-CoV-2 pandemic, much has been discussed about the effectiveness of treatments based on hydroxychloroquine combined with azithromycin or another macrolide. However, few articles have dealt with the possibility of using macrolides alone in treating the disease. In the present article, the authors' hypothesis centers on the possibility that macrolides are effective against SARS-CoV-2 by inhibiting the virus protease. In support of this hypothesis, significant results are collected by following an in silico strategy based on a combination of molecular topology and docking. The results are in accordance with recent clinical data generated during the pandemi…

0301 basic medicineProteaseChemistryIn silicomedicine.medical_treatmentGeneral ChemistryComputational biologyAzithromycinFlurithromycinCatalysisVirus03 medical and health sciences030104 developmental biology0302 clinical medicineDocking (molecular)030220 oncology & carcinogenesisClarithromycinMaterials ChemistrymedicineViral loadmedicine.drugNew Journal of Chemistry
researchProduct